Barry Make
Pulmonary Disease · Denver, CONPI 1801976303
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.1%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2019 at $53,028 and has fallen 60.8% since, to $20,762 in 2025. Among pulmonary disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $1435.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$34K
- Regeneron Healthcare Solutions, Inc.$29K
- Boehringer Ingelheim Taiwan Ltd.$23K
- AstraZeneca$22K
- GSK$19K
- Astrazeneca AB$14K
- plus $21K from 7 others
Across 10 payments — averaging $7667.47 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Circassia Inc.$32K
- AstraZeneca$23K
- Boehringer Ingelheim$16K
- Shire North American Group Inc$4K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
What the payments were for
- Consulting fees$89,43155%
- Speaking & faculty fees$27,65417%
- Travel & lodging$42,46226%
- Food & beverage$2,6212%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 17 | $34,055 |
| Regeneron Healthcare Solutions, Inc. | 23 | $28,575 |
| Boehringer Ingelheim Taiwan Ltd. | 4 | $23,181 |
| AstraZeneca | 28 | $22,147 |
| GSK | 8 | $18,967 |
| Astrazeneca AB | 8 | $14,459 |
| Regeneron | 5 | $7,279 |
| Mylan Specialty L.p. | 10 | $6,390 |
| Sanofi | 2 | $4,802 |
| Boehringer Ingelheim | 2 | $1,984 |
| Genentech USA, Inc. | 4 | $193 |
| Covidien LP | 1 | $72 |
| Pulmonx Corporation | 1 | $63 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$27,947
- STIOLTO$22,243
- TRELEGY ELLIPTA$7,475
- NUCALA$6,175
- Yupelri$6,167
- BREZTRI AEROSPHERE$4,668
- BREZTRI$2,626
- SPIRIVA$1,860
- AIRSUPRA$1,344
- XOLAIR$150
- STIOLTO RESPIMAT$124
- SPIRIVA RESPIMAT$124
- FASENRA$105
How this compares
$162,168 in reported general payments places this provider in the 95th percentile of 248 pulmonary disease providers in Colorado.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $638 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Denver
- Michael WechslerDenver$2.7M
- Ronald BalkissoonDenver$1.2M
- Vamsi GunturDenver$310K
- Kevin BrownDenver$299K
- Rebecca KeithDenver$248K
- Marjorie GeorgeDenver$192K
- Everett SutherlandDenver$174K
- Charles DaleyDenver$166K
- Amy OlsonDenver$117K
- Robert SandhausDenver$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.